Navigation Links
STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
Date:1/14/2010

stelarainfo.com/">www.STELARAinfo.com.

Centocor Ortho Biotech Inc. discovered STELARA and has exclusive marketing rights to the product in the United States.  Janssen-Cilag companies have exclusive marketing rights in all countries outside of the United States.  STELARA is approved in 44 countries around the world including Canada, Europe and the United States for the treatment of moderate-to-severe plaque psoriasis.

Important Safety Information

STELARA™ is a prescription medicine that affects your immune system. STELARA™ can increase your chance of having serious side effects including:

Serious Infections

STELARA™ may lower your ability to fight infections and may increase your risk of infections. While taking STELARA™, some people have serious infections, which may require hospitalization, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses.

  • Your doctor should check you for TB before starting STELARA™ and watch you closely for signs and symptoms of TB during treatment with STELARA™.
  • If your doctor feels that you are at risk for TB, you may be treated for TB before and during treatment with STELARA™.

You should not start taking STELARA™ if you have any kind of infection unless your doctor says it is okay.

Before starting STELARA, tell your doctor if you think you have an infection or have symptoms of an infection such as:

  • fever, sweats, or chills
  • muscle aches
  • cough
  • shortness of breath
  • blood in your phlegm
  • '/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) ... Cava (IVC) Filters - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena ... million by 2016. The North America ... value while Europe claims approximately ...
(Date:12/15/2014)... Norway , December 15, 2014 ... innovative drugs for aggressive drug resistant cancers, today announces ... in a private placing from new and existing investors. ... financing to support the development of its pipeline of ... program for its lead drug candidate, BGB324, a first-in-class ...
(Date:12/15/2014)... Dec. 15, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... been added to the NASDAQ Biotechnology Index (NBI). ... become effective upon market open on December 22, ... designed to track the performance of a set ... biotechnology or pharmaceutical according to the Industry Classification ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
... new understanding of,the role played by the protein ... novel therapies to rebuild muscle tissue,damaged by disease, ... Institute for Cancer Research and Molecular Medicine at ... The researchers reported their findings, "Cdk9-55: A ...
... implantable,medical device, developed in collaboration with Mayo Clinic ... alternative to existing,bariatric surgeries, according to findings published ... In a six-month open label trial involving three ... obese participants who received the,vagal nerve blocking device, ...
Cached Medicine Technology:International Team Locates Key Player in Muscle Regeneration 2Device Blocking Stomach Nerve Signals Shows Promise in Obesity 2Device Blocking Stomach Nerve Signals Shows Promise in Obesity 3
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of ... the Future” and co-founder of the Ace Medical Weight Loss ... takes a broad look at the industry of weight loss, ... scrutiny. On film and in television shows, however, she says ... social aspects and played for basic laughs, which she believes ...
(Date:12/17/2014)... 2014 In its comprehensive analysis of ... Argus Claim Review division have recently identified out-of-network and ... ways savings are achieved on behalf of employer-clients. ... dollars in savings to Argus each year, with a ... explained by Tom Doney, Cypress president and CEO, these ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... one worrisome phenomenon is when an illness that originated in ... as zoonosis -- is not uncommon and keeps researchers on ... disease might make inroads into the human population. A ... the culprits in this case were guinea pigs. More specifically, ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. ... to improve overall health, but a growing body of evidence ... new review finds. In fact, the benefits were similar ... lead researcher Paula Chu, a doctoral candidate at Harvard University,s ... clinical trials, found that people randomly assigned to take yoga ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Main Street ... clinic, is weighing in on a new study providing ... on the oral hygiene of children. , Sufficient enough ... drinks, such as pop or juice drinks, with the ... looming, however, is whether drinks listed as 100% fruit ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
... offers a significantly higher survival rate than either external-beam radiation ... researchers at UCSF. The differences among therapies were more ... researchers say, that in many cases surgery should play a ... that is likely to recur or spread. ...
... Reinberg HealthDay Reporter , THURSDAY, Aug. 5 (HealthDay ... having a miscarriage stand the best chance of having a ... The time that couples should wait after a miscarriage ... among medical experts. Some doctors say there is no reason ...
... HealthDay Reporter , THURSDAY, Aug. 5 (HealthDay News) ... a lowered risk of heart disease and diabetes, being ... of glaucoma, Harvard researchers say. This new finding ... of developing primary open-angle glaucoma (POAG), one of the ...
... Researchers looking for differences in eating habits of African ... diabetes uncovered an unexpected result: No matter what the blood ... same. African Americans are 1.8 times more likely to ... be obese than are non-Hispanic whites, according to federal health ...
... published today in the scientific journal Addiction ... the manufacture of methamphetamine have caused a drop in ... In 2005 Mexico began controlling its ... manufacture of methamphetamine), and in 2008 it became the ...
... hard to find, here,s good news for the under-qualified: ... ( http://www.fasebj.org ) shows that being a highly ... taking on leading management positions at research institutions. This ... may exist at research institutions where top-cited scientists either ...
Cached Medicine News:Health News:Surgery better than radiation, hormone treatments for some prostate cancer, study shows 2Health News:Surgery better than radiation, hormone treatments for some prostate cancer, study shows 3Health News:Women Can Safely Get Pregnant Right After Miscarriage, Study Shows 2Health News:Women Can Safely Get Pregnant Right After Miscarriage, Study Shows 3Health News:Excess Weight May Protect Women From Type of Glaucoma 2Health News:Excess Weight May Protect Women From Type of Glaucoma 3Health News:Diabetes or not, dietary habits of Aftrican-Americans are similar 2Health News:Diabetes or not, dietary habits of Aftrican-Americans are similar 3Health News:Diabetes or not, dietary habits of Aftrican-Americans are similar 4Health News:Help wanted: Highly cited researchers needed for high-ranking positions at research institutions 2
... in the field of Urodynamics, Albyn Medical recognised ... new chair is manufactured from the highest quality ... can be improved considerably if the patient is ... this aspect was given a high priority in ...
The Triage Drugs of Abuse Panel is the leading rapid drug screen used by U.S. hospitals. The Triage Drugs of Abuse Panel is a small, handheld urine test that provides qualitative results for up to n...
... The Advanced Model 3900 Multi-Sample ... for laboratories processing moderate to high ... industry-preferred method of freezing-point technology for ... combined with high, continuous throughput, the ...
... The Advanced® 2020 Multi-Sample Osmometer provides ... industrial, and research settings. These results ... freezing-point method, which determines total concentration. ... on-board data management, automated sample handling, ...
Medicine Products: